Cognitive Impairments in Patients with Ischemic Stroke and Their Correction

The efficacy of prolonged use of the cytoprotective neuropeptide Cortexin on cognitive impairments was studied in patients with ischemic stroke. A total of 80 patients with first ischemic strokes were studied. Patients of the study group ( n = 40) received basal treatment plus 10 mg i.m. Cortexin once daily for 10 days, with repeat courses given at three, six, and nine months during the first year; control patients ( n = 40) received only basal treatment. Use of four courses of Cortexin over one year in patients with ischemic stroke promoted stabilization and recovery of cognitive functions, and also minimized the probability of post-stroke cognitive impairments throughout the recovery period.